Biotest
Dimitri Vangheel has a range of work experience in the pharmaceutical and biotechnology industries. Dimitri started their career at Alcon, a Novartis Division, where they served as a Supervisor in Production from 2013 to 2016. Dimitri then moved to Prothya Biosolutions, where they held various roles including Assistant Manager in Production, Head of Production, Manager in Process Engineering, Senior Manager in Engineering, and Vice President in Engineering from 2016 to 2023. Dimitri also gained experience as a Board Member for both ISPE Belgium Affiliate vzw and YP ISPE from 2018 to 2021. Most recently, they joined Biotest AG as the VP of Project Engineering in 2023.
Dimitri Vangheel studied Ingenieurswetenschappen at KU Leuven from 2010 to 2012, and obtained a Master's degree in Ingenieur Chemische processen from Artesis Hogeschool Antwerpen between 2006 and 2010.
This person is not in any offices
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.